The European Union Began to Evaluate the Chinese Vaccine Against Coronavirus “Vero Cell”
OREANDA-NEWS. The European Medicines Agency (EMA) has begun a rolling review of the Chinese Vero Cell coronavirus vaccine. This is stated in the agency's message.
"The EMA Human Medicines Committee has begun a rolling review process for the COVID-19 Vaccine (Vero Cell) Inactivated vaccine developed by Sinovac Life Sciences," the release said.
The decision to initiate this evaluation is based on preliminary laboratory findings and clinical studies that suggest the vaccine triggers the production of antibodies that target SARS-CoV-2, the virus that causes COVID-19, and may help protect against disease.
The release also notes that “EMA will examine the data as it becomes available to decide if the advantages of the vaccine outweigh its potential risks. The rolling review will continue until sufficient evidence is available to apply formally for marketing authorization in the European Union. "
The EU regulator will assess the vaccine's compliance with EU standards for efficacy, safety and quality.
Currently, three more vaccines are being evaluated using rolling review procedure: the Russian Sputnik V, as well as CVnCoV from CureVac, NVX-CoV2373 from Novavax.
Four drugs are now authorized centrally across the EU: from Pfizer / BioNTech, Moderna, AstraZeneca and Johnson & Johnson. In addition, the EC has entered into contracts for the supply of vaccines for the entire EU with the French-British Sanofi-GSK and the German CureVac.